Staar Surgical Company ( (STAA) ) has released its Q2 earnings. Here is a breakdown of the information Staar Surgical Company presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
STAAR Surgical Company, a leader in the field of ophthalmic surgery, specializes in implantable phakic intraocular lenses (ICLs) designed for vision correction, offering a minimally invasive alternative to glasses or contact lenses. Headquartered in Lake Forest, California, the company has a global presence with operations in over 75 countries.
In its latest earnings report for the second quarter of 2025, STAAR Surgical reported net sales of $44.3 million, a significant decrease of 55% compared to the same period last year. This decline was primarily due to a planned reduction of channel inventory in China. However, excluding China, the company saw a 10% increase in net sales, highlighting growth in other regions.
Key financial metrics for the quarter included a gross margin of 74.0%, down from 79.2% a year ago, and a net loss of $16.8 million, compared to a net income of $7.4 million in the previous year. Operating expenses were reduced due to cost optimization efforts, with total operating expenses at $62.8 million, down from $66.5 million in the prior year. The company also repurchased approximately 261,000 shares of its common stock as part of a $30 million share repurchase program.
Despite the challenges faced in the Chinese market, STAAR Surgical’s management remains focused on growth in other regions and continues to optimize costs. With the pending acquisition by Alcon Inc., the company is poised for strategic changes that could influence its future trajectory.